Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting
The following AR-67 poster presentations will be presented during the Developmental Therapeutics Session: Cytotoxic Chemotherapy general poster session on Saturday, May 30, from 8:00 AM to 12:00 PM ET, on level 2 in West Hall C:
The above poster presentations describe findings from the Phase I trial of AR-67 in cancer patients with a broad range of solid tumor types whose tumors had progressed on prior treatment regimens.
AR-67 is a novel, third-generation camptothecin analogue that has demonstrated high potency in preclinical studies and improved pharmacokinetic properties, compared with approved second-generation products, as demonstrated by the increased stability of the active lactone form of AR-67 in blood. Moreover, the potential for oral administration may increase patient convenience.
Arno has completed a Phase I single agent, clinical study of AR-67 in patients with advanced solid tumors. The study has established the maximum tolerated dose, and is evaluating the safety as characterizing the plasma Pk profile of AR-67. A Phase II study is planned for initiation during 2009 in glioblastoma multiforme (GBM) a highly aggressive form of brain cancer and a Phase II study is planned for initiation during 2009 in myelodysplastic syndrome (MDS).
About Arno Therapeutics
Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead clinical development compound is AR-67, a novel, third-generation camptothecin analogue which has completed patient enrollment of its Phase I studies in patients with advanced solid tumors, that has demonstrated high preclinical potency and improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two additional drug candidates. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the endoplasmic reticulum stress pathway, that received FDA acceptance of its IND in the second quarter of 2009. AR-42, an orally available, targeted inhibitor of the Pan-DAC and Akt pathways received FDA acceptance of its IND in the first quarter of 2009.
For more information on Arno please visit www.arnothera.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings, as well as our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management, are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of our product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Arno is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Contact: Arno Therapeutics, Inc.
Brian Lenz, CPA, 862-703-7175
Chief Financial Officer
Posted: May 2009